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Abstract
Background—Previous studies documented racial/ethnic and socioeconomic disparities in 
survival after Hodgkin lymphoma (HL) among adolescents and young adults (AYAs), but did not 
consider the influence of combined-modality treatment and health insurance.
Methods—Data for 9,353 AYA patients aged 15–39 when diagnosed with HL during 1988–2011 
were obtained from the California Cancer Registry. Using multivariate Cox proportional hazards 
regression, we examined the impact of socio-demographic characteristics (race/ethnicity, 
neighborhood socioeconomic status (SES), and health insurance), initial combined-modality 
treatment, and subsequent cancers on survival.
Results—Over the 24-year study period, we observed improvements in HL-specific survival by 
diagnostic period and differences in survival by race/ethnicity, neighborhood SES and health 
insurance for a subset of more recently diagnosed patients (2001–2011). In multivariable analyses, 
HL-specific survival was worse for Blacks than Whites with early-stage (Hazard Ratio (HR): 1.68; 
95% Confidence Interval (CI): 1.14, 2.49) and late-stage disease (HR: 1.68; 95% CI: 1.17, 2.41) 
and for Hispanics than Whites with late-stage disease (HR: 1.58; 95% CI: 1.22, 2.04). AYAs 
diagnosed with early-stage disease experienced worse survival if they also resided in lower SES 
neighborhoods (HR: 2.06; 95% CI: 1.59, 2.68). Furthermore, more recently diagnosed AYAs with 
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public health insurance or who were uninsured experienced worse HL-specific survival (HR: 2.08; 
95% CI: 1.52, 2.84).
Conclusion—Our findings identify several subgroups of HL patients at higher risk for HL 
mortality.
Impact—Identifying and reducing barriers to recommended treatment and surveillance in these 
AYAs at much higher risk of mortality is essential to ameliorating these survival disparities.
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Introduction
For Hodgkin lymphoma (HL), one of the most common cancers of adolescents and young 
adults (AYAs) 15 to 39 years of age (1), treatment with combined-modality (radiation plus 
chemotherapy) regimens has led to substantial improvements in survival over time and has 
been commonly recommended for patients with limited stage disease and those with bulky, 
advanced stage disease (2, 3). However, these impressive survival gains have not been 
shared uniformly across the AYA population, as worse outcomes have been documented for 
15–44 year-olds of lower neighborhood socioeconomic status (SES) (4) and non-White race/
ethnicity (4, 5).
Among explanations for these disparities, the similarity of disparities for overall and HL-
specific survival (4) and the persistent difference in relative survival by neighborhood SES 
over time (4), implicate variations in initial treatment and management more than variations 
in the late complications sometimes resulting from HL (6). We previously found that Blacks 
(52%) and Hispanics (47%) were more likely to receive chemotherapy alone (as compared 
with combined-modality) than non-Hispanic Whites (38%) or Asian/Pacific Islanders (APIs) 
(40%) 15–44 years of age (4). Recent (1995–2010) population-based data on AYAs with 
early-stage HL also showed that Blacks and Hispanics, and patients residing in lower SES 
neighborhoods had lower utilization of radiation therapy, and Blacks and Hispanics, and 
AYAs not receiving radiation had higher mortality (7).
In addition, inadequate health insurance is associated with later stage at diagnosis, under-
treatment and worse survival (8–12). Adult (≥18 years) HL patients with early stage disease 
who were uninsured were less likely to receive chemotherapy and radiation (12), and AYAs 
who were uninsured, had public health insurance or resided in lower SES neighborhoods 
were more likely to be diagnosed with advanced-stage HL (11).
In efforts to date to understand HL survival disparities, no prior studies have considered the 
influence of both receipt of initial combined-modality treatment and insurance on the racial/
ethnic and socioeconomic disparities in survival among AYAs diagnosed with all stages of 
HL. Therefore, to identify socio-demographic patient subgroups that have not benefited 
from well-established and effective treatments, we evaluated the impact of socio-
demographic characteristics (race/ethnicity, neighborhood SES and health insurance), initial 
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combined-modality treatment, and subsequent cancers on survival among AYAs diagnosed 
with early and late stage HL.
Materials and Methods
Patients
Patients eligible for the study were all persons who resided in California when newly 
diagnosed at ages 15 through 39 years with classical HL (International Classification of 
Diseases—Oncology, 3rd edition (13) morphology codes 9650–9655, 9663–9667) during the 
period January 1, 1988 through December 31, 2011 and reported to the California Cancer 
Registry (CCR). From the CCR, which operates under a state cancer reporting law and 
comprises three National Cancer Institute (NCI) Surveillance, Epidemiology and End 
Results (SEER) registries, we obtained information routinely recorded in the medical record 
at diagnosis for each patient on age, sex, race/ethnicity (non-Hispanic White (hereafter 
called “White”), Hispanic, Black, and API), summary stage (localized (Ann Arbor stage I), 
regional (stage II), advanced (stage III/IV)), extent of disease, tumor histologic subtype 
(nodular sclerosis, mixed cellularity, lymphocyte depletion, lymphocyte rich, or not 
otherwise specified), marital status (never married, married, previously married, unknown), 
hospital providing initial care, and census-block group of residence. With information on 
extent of disease, we classified patients by the presence of B symptoms (weight loss, night 
sweats, and fever) and human immunodeficiency virus (HIV) or acquired immunodeficiency 
syndrome (AIDS). In addition, we obtained registry data on initial treatment modality 
(radiation (yes, no, unknown) and chemotherapy (yes, no, unknown)), from which we 
created a combined modality measure; subsequent primary cancer(s) reported during the 
study period; vital status (routinely determined by the CCR through hospital follow-up and 
linkages to state and national vital status and other databases) as of December 2012; and, for 
the deceased, the underlying cause of death as routinely coded by state vital statistics 
personnel.
We also obtained information on the primary source of payment at initial diagnosis and/or 
treatment (health insurance), which was reportable to the CCR for patients diagnosed from 
2001 forward. Health insurance was grouped into public (Medicaid and other government-
assisted programs), private (health maintenance organizations, preferred provider 
organizations, managed care not otherwise specified, and military care), none and unknown 
(11). Consistent with prior observations that the small percentage of AYA cancer patients 
who were uninsured likely reflect retroactive enrollment in Medicaid at the time of cancer 
diagnosis (9), we considered publicly insured and uninsured together in the survival 
analyses. Hospitals were classified according to whether or not they were NCI-designated 
cancer centers.
We used a multi-component index of neighborhood SES based on patients’ residential 
census-block group at diagnosis. The index is derived from data from the 2000 U.S. Census 
(for cases diagnosed through 2005) and the 2006–2010 American Community Survey (for 
cases diagnosed in 2006 forward) on education, occupation, unemployment, household 
income, poverty, rent, and house values (14). The indices are grouped into quintiles, based 
on the distribution of SES across all census block groups in California, and, as done 
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previoulsy (4), into one of two categories for models stratified by stage at diagnosis: lower 
SES (quintiles 1, 2 and 3) and higher SES (quintiles 4 and 5). Each cancer case was assigned 
to his/her neighborhood SES category. Based upon the population density of census blocks 
(15, 16), we defined urbanization level as metropolitan (metropolitan urban and 
metropolitan suburban blocks), non-metropolitan (city, town and rural blocks) or unknown.
The final study population included 9,353 AYA HL patients after exclusion, in a 
hierarchical manner, of those with: 1) unknown race/ethnicity (n=166); 2) cancer registry or 
death certificate evidence of HIV or AIDS (17) (n=262), because of the substantially poorer 
outcome of HIV-associated HL during the study period (18, 19); 3) HL diagnosis at autopsy 
only, by death certificate only, or with zero/invalid survival time (n=40). All study protocols 
were overseen by the Institutional Review Board of the Cancer Prevention Institute of 
California.
Statistical analyses
Outcomes of interest included overall survival, which considers death from all causes, and 
HL-specific survival, which considers only death from HL. For deceased patients, survival 
time was measured in days from the date of diagnosis to the date of death from any cause for 
overall survival, and to the date of death from HL for HL-specific survival. Patients who 
died from other causes were censored at the time of death in analyses of HL-specific 
survival. Patients alive at the study end date (12/31/2012) were censored at this time or at 
the date of last known contact. Ninety-four percent of censored patients had a follow-up date 
within two years of the study end date but this number was slightly higher for Whites (95%), 
Blacks (96%), and APIs (95%) than for Hispanics (89%).
To evaluate associations with survival (overall and HL-specific) controlling for known 
prognostic factors, we used multivariable Cox proportional hazards regression to estimate 
hazard ratios (HRs) and associated 95% confidence intervals (CIs). Models included 
variables with a priori reasons for inclusion (e.g., age, race/ethnicity, gender, year of 
diagnosis, marital status, B symptoms, histologic subtype, hospital type, neighborhood SES 
and urbanization, and insurance status) and included stage at diagnosis, combined-modality 
therapy, and subsequent cancer as stratifying variables to allow for differing baseline 
hazards associated with these variables. Additionally, separate Cox proportional hazards 
models were conducted by stage at diagnosis. Effect modification was assessed between 
SES and stage at diagnosis, health insurance, and gender; between race/ethnicity and SES, 
health insurance, and stage at diagnosis; and between age and marital status, by including 
interaction terms in the multivariable models. No interaction terms were statistically 
significant at p<0.05. In all models, the proportional hazards assumption was assessed 
numerically based on cumulative sums of Martingale residuals (20) and visually based on 
inspection of the survival curves (log (−log) of the survival distribution function by log 
(months)). There was evidence of a violation of this assumption with stage at diagnosis, 
combined-modality therapy and subsequent cancers; therefore, stratified Cox proportional 
hazards regression models are presented. Regression analyses were conducted using SAS 
version 9.3 software (SAS institute Inc., Cary, NC, USA).
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In this cohort of 9,353 AYA HL patients, 32% were followed for 15 years or more, with the 
mean follow-up time of 11.0 years (std=7.1). Socio-demographic and clinical characteristics 
of AYA HL patients varied by race/ethnicity, with a predominance of Whites (63%) and, to 
a lesser extent, Hispanics (24%), and an increasing proportion of Asians over time (Table 1). 
Black (40%) and Hispanic (37%) AYAs were more likely to be diagnosed at an advanced 
stage than Whites (31%) or APIs (34%), and higher percentages of Black (54%) and 
Hispanic (49%) AYAs received chemotherapy alone than Whites (40%) or APIs (42%). 
More than 73% of Blacks and Hispanics resided in the lowest three categories of 
neighborhood SES compared to fewer than 47% of Whites and APIs. Blacks (35%) and 
Hispanics (39%) were much more likely to have public or no insurance than Whites (17%) 
or APIs (16%). Nearly 6% of AYA HL patients were diagnosed with a subsequent primary 
cancer. As of December 2012, more than 13% of AYA HL patients had died, predominantly 
from cancer (72%).
In multivariable analyses, worse HL-specific survival was associated with male sex 
(borderline significance), earlier year of diagnosis, and presence of B symptoms (Table 2). 
Black AYAs experienced a 62% higher risk of HL death (hereafter referred to as mortality) 
(HR: 1.62; 95% CI: 1.24, 2.11) and Hispanics experienced a 35% higher risk of HL 
mortality (HR: 1.35; 95% CI: 1.12, 1.64) than Whites. In addition, AYAs residing in lower 
SES neighborhoods experienced a 52% to 77% greater risk of HL mortality than those 
residing in the highest SES neighborhood categories. Worse overall survival (Table 2) was 
associated with many of the same factors as HL-specific survival, except that earlier age at 
diagnosis was associated with better all-cause survival.
AYAs with public or no insurance experienced much worse HL-specific survival (HR: 2.08; 
95% CI: 1.52, 2.84) than those with private or military insurance (Table 2). The addition of 
health insurance to the multivariable models attenuated the hazard ratios for race/ethnicity 
by less than 9%, but attenuated the hazard ratios for neighborhood SES by up to 22%. 
Nevertheless, the hazard ratio for HL-specific survival comparing the highest neighborhood 
SES to the lowest was still evident, although of borderline significance (HR: 1.67; 95% CI: 
0.97, 2.86; data not shown in tables).
In separate models for stage at diagnosis (Table 3), Blacks with early- and late-stage disease 
experienced a 68% greater risk of HL mortality, while Hispanics with late-stage, but not 
early-stage, disease experienced a greater risk of HL mortality (HR: 1.58; 95% CI: 1.22, 
2.04). In addition, the association between lower neighborhood SES and HL-specific 
survival only was apparent among AYAs diagnosed with early-stage disease (HR: 2.06; 
95% CI: 1.59, 2.68). AYAs with early or late-stage disease experienced greater than a two-
fold increased risk of HL mortality if they had public or no insurance. Worse overall 
survival by stage at diagnosis (Table 3) was associated with many of the same factors as 
HL-specific survival.
The use of radiation in HL treatment decreased over time (Figure 1). To compare our results 
to those in prior studies (7, 12), we also examined the impact of initial combined-modality 
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therapy on survival as an adjustment variable (rather than a stratifying variable due the 
violation of the proportional hazards assumption). We found that initial treatment with 
radiation was associated with better HL-specific survival (HR for chemotherapy and 
radiation (vs. chemotherapy only): 0.85; 95% CI: 0.71, 1.02; HR for radiation only (vs. 
chemotherapy only): 0.34; 95% CI: 0.23, 0.51; data not shown in tables). These associations 
were similar for early- and late-stage disease (Figure 2).
Discussion
In this population-based study of more than 9,000 AYAs diagnosed with HL over a 24-year 
period, we observed improvements in survival over time, but also striking disparities in 
survival by race/ethnicity, neighborhood SES and health insurance for a subset of more 
recently diagnosed patients. In particular, Blacks (regardless of disease stage) and Hispanics 
with late-stage disease experienced worse survival than Whites. In addition, AYAs 
diagnosed with early-stage disease experienced worse survival if they also resided in lower 
SES neighborhoods. Furthermore, more recently diagnosed AYAs with public health 
insurance or no insurance experienced greater than a two-fold increased risk of HL 
mortality. Together, these findings identify vulnerable subgroups of HL patients at higher 
risk for HL mortality and point to disparities in treatment delivery and follow-up care as 
likely contributing factors.
Our previous work in outcomes for young adult HL patients suggested that survival 
disparities by race/ethnicity or neighborhood SES may be due to variations in initial 
treatment and management (4). Consistent with studies that found initial treatment to vary 
by race/ethnicity (4, 7), neighborhood SES (7), and health insurance (12), we also observed 
that Blacks and Hispanics, AYAs residing in lower SES neighborhoods, and AYAs with 
public or no insurance were more likely to receive chemotherapy alone as initial treatment. 
Our group and others (7, 12) also found that these disparities in treatment were associated 
with worse survival. Despite the survival benefits of radiation, this therapy has been 
associated with subsequent primary malignancies (6, 7, 21), an outcome that we were able to 
consider in our analyses. Specifically, we found that a somewhat higher proportion of 
patients who received radiation for their HL had subsequent cancer (4.9% versus 6.9%), 
which was associated with worse overall survival (data not shown); modern treatments with 
lower doses of radiation (7) may result in fewer subsequent cancers (21) and should 
continue to be monitored. However, even after controlling for initial treatment and 
subsequent cancers, we still observed differences in survival by race/ethnicity, neighborhood 
SES and health insurance, suggesting that other factors are influencing these associations.
Expanding on a prior study that found AYA HL patients who were uninsured or had public 
health insurance were more likely to be diagnosed with advanced-stage HL (11), we found 
that AYA HL patients with these types of insurance experienced worse HL-specific survival, 
whether they had early- or late-stage disease. In studies of AYA cancer survivors, health 
insurance rates have been found to decrease with time from diagnosis (22, 23), particularly 
for older AYAs and those with less education (23), and a lack of health insurance is a barrier 
to receiving any medical care (22, 24). Further, more than two-thirds of uninsured survivors 
have been found to have no personal provider or routine medical care and, even with health 
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insurance, AYA cancer survivors are more likely to forgo medical care due to costs (24). 
Collectively, these results suggest that health insurance is a critical barrier to receiving 
cancer-related medical care that can impact prognosis. While the implementation of the 
measures from the Patient Protection and Affordable Care Act (ACA) of 2010 and 2014 (25, 
26) should improve AYA cancer survivors’ access to health insurance, studies should 
continue to monitor barriers to health insurance enrollment and medical care in AYAs.
Our findings of worse survival among Blacks and Hispanics and AYAs with HL residing in 
lower SES neighborhoods are consistent with those of prior studies (4, 7). We observed 
some differences by stage at diagnosis: the impact of neighborhood SES was stronger for 
early-stage disease and Hispanics with late-stage disease experienced worse HL survival. 
Although we did not have health insurance information for AYAs throughout our study 
period, it is likely that factors beyond health insurance are influencing these race/ethnicity 
and neighborhood SES associations. Inadequate long-term follow-up in patients could result 
in a delay in diagnosing and treating complications (27), particularly for AYAs, who tend to 
lack knowledge about their higher risk for developing complications (28–30). Financial 
concerns, including lost wages, copayments, high deductibles, childcare and transportation 
costs (24, 31–33) can be burdensome and influence follow-up care, particularly for AYAs 
with financial limitations (e.g., debt from college or starting a career). In addition, if poor 
health behaviors and comorbid conditions are more prevalent in lower-SES and/or non-
White HL patients, as found for patients with other cancers (34–38), these factors, too, could 
increase post-treatment complications and reduce survival.
Our study is subject to some limitations. We considered the first course of treatment, but 
lacked details (e.g., dosing) on chemotherapy, radiation and other treatment received after 
this period, and there is the potential for radiation (39, 40) and chemotherapy (40) to be 
under-ascertained; therefore, our findings could be subject to residual confounding from 
incomplete treatment data (41). While it is possible that our findings are partially influenced 
by indication bias (i.e., patients who received radiation alone had more favorable disease 
characteristics and thus more favorable outcomes), it is also possible that some patients 
received radiation alone because they had comorbidities that precluded use of 
chemotherapy. Given that combined-modality therapy was broadly recommended by 
guidelines across all stages of HL during the study period (2, 3), the most plausible 
explanation for improved survival among patients who received radiation alone is under-
ascertainment of chemotherapy, particularly for patients with advanced-stage disease. We 
were unable to consider health insurance at diagnosis for patients diagnosed before 2001, 
and lacked information on changes to health insurance after initial treatment, treatment 
adherence or quality of care--factors that can influence subsequent care and outcomes. We 
also were unable to determine if patients were undocumented and ineligible for public health 
insurance. Because cancer registry data do not include potentially relevant clinical data such 
as prognostic serum measures (42), International Prognostic Index, or prognostic tumor 
characteristics (e.g., presence of Epstein-Barr virus in tumor cells (5)), or information on 
lifestyle behaviors or comorbid conditions, our analyses could not examine the impact of 
these factors on survival. Our study also lacked individual-level measures of SES to 
consider separately or with our neighborhood measure. While neighborhood and individual 
SES are associated, neighborhood SES has been found to underestimate associations 
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observed with individual-level SES (43). However, our multifaceted measure of 
neighborhood SES at the block group-level incorporated several domains of education, 
income, employment, and cost of living that capture various elements of the socioeconomic 
environment that may augment individual-level SES. Our study may also be subject to 
potential misclassification of race/ethnicity, although we previously have detected excellent 
overall agreement with self-reported race/ethnicity for Whites and Blacks, and good 
agreement for Hispanics and Asians (44, 45).
Despite these limitations, this study was population-based and included a large diverse 
population of AYA HL cancer patients who received their care across all types of 
institutions, increasing the generalizability of these findings. In addition, our study is one of 
the first to consider the influence of initial combined-modality treatment and health 
insurance on previously noted racial/ethnic and socioeconomic disparities in survival among 
AYAs diagnosed with early-and late-stage HL.
This study found that AYA HL patients of Black or Hispanic race/ethnicity, those who 
resided in lower SES neighborhoods, and those who were uninsured or publicly insured 
experienced worse HL-specific survival. While prior studies have noted these racial/ethnic 
and SES survival disparities, our study extends these previous efforts by considering 
combined-modality treatment, subsequent primary cancers and health insurance. With 
uninsurance rates historically peaking in adolescence and young adulthood (46), AYA HL 
patients may be particularly vulnerable to failing to receive cancer survivor-focused medical 
care. The ACA has the potential to influence both access to insurance and use of necessary 
health care for AYAs and should be evaluated in future studies. In addition, identifying and 
reducing barriers to recommended treatment and surveillance in these AYAs at higher risk 
of mortality is essential to ameliorating these survival disparities.
Acknowledgments
Financial support: This work was supported by the Stanford Cancer Institute (T.H.M. Keegan), the Cancer 
Prevention Institute of California (S.L. Glaser), the National Cancer Institute’s Surveillance, Epidemiology and End 
Results Program under contract HHSN261201000140C awarded to the Cancer Prevention Institute of California 
(M.C. DeRouen, C.A. Clarke, D. Goldberg), and a National Cancer Institute Career Development Award (H.M. 
Parsons, K07CA175063). The funders did not have any role in the design and conduct of the study; collection, 
management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision 
to submit the manuscript for publication.
The collection of cancer incidence data used in this study was supported by the California Department of Public 
Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 
103885; the National Cancer Institute’s Surveillance, Epidemiology and End Results Program under contract 
HHSN261201000140C awarded to the Cancer Prevention Institute of California, contract HHSN261201000035C 
awarded to the University of Southern California, and contract HHSN261201000034C awarded to the Public 
Health Institute; and the Centers for Disease Control and Prevention’s National Program of Cancer Registries, 
under agreement U58DP003862-01 awarded to the California Department of Public Health. The ideas and opinions 
expressed herein are those of the author(s) and endorsement by the State of California, Department of Public Health 
the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and 
Subcontractors is not intended nor should be inferred.
C.A. Clarke received research funding from Genentech unrelated to the submitted work.
Keegan et al. Page 8














1. Howlader, N.; Noone, AM.; Krapcho, M.; Garshell, J.; Miller, D.; Altekruse, SF.; Kosery, CL.; Yu, 
M.; Ruhl, J.; Tatalovich, Z.; Cho, H.; Mariotto, A.; Lewis, DR.; Chen, HS.; Feuer, EJ.; Cronin, KA., 
editors. SEER Cancer Statistics Review, 1975–2012. Bethesda, MD: National Cancer Institute; 
2015. http://seer.cancer.gov/csr/1975_2012/ based on November 2014 SEER data submission, 
posted to the SEER web site, April 2015 ed.
2. Das P, Ng A, Constine LS, Advani R, Flowers C, Friedberg J, et al. ACR Appropriateness 
Criteria(R) on Hodgkin's lymphoma-unfavorable clinical stage I and II. J Am Coll Radiol. 2011; 
8:302–308. [PubMed: 21531305] 
3. Terezakis SA, Metzger ML, Hodgson DC, Schwartz CL, Advani R, Flowers CR, et al. ACR 
Appropriateness Criteria Pediatric Hodgkin Lymphoma. Pediatr Blood Cancer. 2014; 61:1305–
1312. [PubMed: 24616347] 
4. Keegan TH, Clarke CA, Chang ET, Shema SJ, Glaser SL. Disparities in survival after Hodgkin 
lymphoma: a population-based study. Cancer Causes Control. 2009; 20:1881–1892. [PubMed: 
19557531] 
5. Keegan TH, Glaser SL, Clarke CA, Gulley ML, Craig FE, Digiuseppe JA, et al. Epstein-Barr virus 
as a marker of survival after Hodgkin's lymphoma: a population-based study. J Clin Oncol. 2005; 
23:7604–7613. Epub 2005 Sep 26. [PubMed: 16186595] 
6. Jachimowicz RD, Engert A. The challenging aspects of managing adolescents and young adults 
with Hodgkin's lymphoma. Acta Haematol. 2014; 132:274–278. [PubMed: 25228552] 
7. Xavier AC, Costa LJ. Changes in the use of radiation therapy for early classical Hodgkin lymphoma 
in adolescents and young adults: implications for survival and second malignancies. Leuk 
Lymphoma. 2015; 56:2339–2343. [PubMed: 25393805] 
8. Aizer AA, Falit B, Mendu ML, Chen MH, Choueiri TK, Hoffman KE, et al. Cancer-specific 
outcomes among young adults without health insurance. J Clin Oncol. 2014; 32:2025–2030. 
[PubMed: 24888800] 
9. Rosenberg AR, Kroon L, Chen L, Li CI, Jones B. Insurance status and risk of cancer mortality 
among adolescents and young adults. Cancer. 2015; 121:1279–1286. [PubMed: 25492559] 
10. Robbins AS, Lerro CC, Barr RD. Insurance status and distant-stage disease at diagnosis among 
adolescent and young adult patients with cancer aged 15 to 39 years: National Cancer Data Base, 
2004 through 2010. Cancer. 2014; 120:1212–1219. [PubMed: 24474656] 
11. Smith EC, Ziogas A, Anton-Culver H. Association between insurance and socioeconomic status 
and risk of advanced stage Hodgkin lymphoma in adolescents and young adults. Cancer. 2012; 
118:6179–6187. [PubMed: 22736071] 
12. Olszewski AJ, Shrestha R, Castillo JJ. Treatment selection and outcomes in early-stage classical 
hodgkin lymphoma: analysis of the national cancer data base. J Clin Oncol. 2015; 33:625–633. 
[PubMed: 25584010] 
13. Fritz, F.; Percy, C.; Jack, A.; Shanmugaratnan, K.; Sobin, L.; Parkin, DM., et al., editors. 
International Classification onf Diseases for Oncology. Third. Geneva: World Health 
Organization; 2000. 
14. Yost K, Perkins C, Cohen R, Morris C, Wright W. Socioeconomic status and breast cancer 
incidence in California for different race/ethnic groups. Cancer Causes Control. 2001; 12:703–711. 
[PubMed: 11562110] 
15. Reynolds P, Hurley SE, Quach AT, Rosen H, Von Behren J, Hertz A, et al. Regional variations in 
breast cancer incidence among California women, 1988–1997. Cancer Causes Control. 2005; 
16:139–150. [PubMed: 15868455] 
16. Urayama KY, Von Behren J, Reynolds P, Hertz A, Does M, Buffler PA. Factors associated with 
residential mobility in children with leukemia: implications for assigning exposures. Ann 
Epidemiol. 2009; 19:834–840. [PubMed: 19364662] 
17. Clarke CA, Glaser SL. Population-based surveillance of HIV-associated cancers: utility of cancer 
registry data. J Acquir Immune Defic Syndr. 2004; 36:1083–1091. [PubMed: 15247562] 
18. Vaccher E, Spina M, Tirelli U. Clinical aspects and management of Hodgkin's disease and other 
tumours in HIV-infected individuals. Eur J Cancer. 2001; 37:1306–1315. [PubMed: 11423262] 
Keegan et al. Page 9













19. Glaser SL, Clarke CA, Gulley ML, Craig FD, DiGiuseppe JA, Dorfman RF, et al. Population-
based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San 
Francisco Bay Area, 1988–1998. Cancer. 2003; 98:300–309. [PubMed: 12872349] 
20. Lin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of martingale-based 
residuals. Biometrika. 1993; 80:557–572.
21. LeMieux MH, Solanki AA, Mahmood U, Chmura SJ, Koshy M. Risk of second malignancies in 
patients with early-stage classical Hodgkin's lymphoma treated in a modern era. Cancer Med. 
2015; 4:513–518. [PubMed: 25620577] 
22. Keegan TH, Tao L, DeRouen MC, Wu XC, Prasad P, Lynch CF, et al. Medical care in adolescents 
and young adult cancer survivors: what are the biggest access-related barriers? J Cancer Surviv. 
2014; 8:282–292. [PubMed: 24408440] 
23. Parsons HM, Schmidt S, Harlan LC, Kent EE, Lynch CF, Smith AW, et al. Young and uninsured: 
Insurance patterns of recently diagnosed adolescent and young adult cancer survivors in the AYA 
HOPE study. Cancer. 2014; 120:2352–2360. [PubMed: 24899580] 
24. Kirchhoff AC, Lyles CR, Fluchel M, Wright J, Leisenring W. Limitations in health care access and 
utilization among long-term survivors of adolescent and young adult cancer. Cancer. 2012; 
118:5964–5972. [PubMed: 23007632] 
25. Moy B, Polite BN, Halpern MT, Stranne SK, Winer EP, Wollins DS, et al. American Society of 
Clinical Oncology policy statement: opportunities in the patient protection and affordable care act 
to reduce cancer care disparities. J Clin Oncol. 2011; 29:3816–3824. [PubMed: 21810680] 
26. Wolfson J, Ruccione K, Reaman GH. Health care reform 2010: expected favorable impact on 
childhood cancer patients and survivors. Cancer J. 2010; 16:554–562. [PubMed: 21131785] 
27. Soares A, Biasoli I, Scheliga A, Luiz RR, Costa MA, Land M, et al. Socioeconomic inequality and 
short-term outcome in Hodgkin's lymphoma. Int J Cancer. 2007; 120:875–879. [PubMed: 
17131320] 
28. Green DM. Late effects of treatment for cancer during childhood and adolescence. Curr Probl 
Cancer. 2003; 27:127–142. [PubMed: 12748582] 
29. Zeltzer LK, Lu Q, Leisenring W, Tsao JC, Recklitis C, Armstrong G, et al. Psychosocial outcomes 
and health-related quality of life in adult childhood cancer survivors: a report from the childhood 
cancer survivor study. Cancer Epidemiol Biomarkers Prev. 2008; 17:435–446. [PubMed: 
18268128] 
30. Casillas J, Kahn KL, Doose M, Landier W, Bhatia S, Hernandez J, et al. Transitioning childhood 
cancer survivors to adult-centered healthcare: insights from parents, adolescent, and young adult 
survivors. Psychooncology. 2010; 19:982–990. [PubMed: 20017115] 
31. Brown, ML.; Yabroff, KR. Economic impact of cancer in the United States. In: Schottenfeld, 
DFJJ., editor. Cancer Epidemiology and Prevention. 3rd. New York, NY: Oxford Univ; 2006. p. 
202-214.
32. Gruber J, Perry I. Will the Affordable Care Act make health insurance affordable? Issue Brief 
(Commonw Fund). 2011; 2:1–15. [PubMed: 21539012] 
33. Nicholson JL, Collins SR. Young, uninsured, and seeking change: health coverage of young adults 
and their views on health reform. Findings from the Commonwealth fund Survey of Young Adults 
(2009). Issue Brief (Commonw Fund). 2009; 73:1–22. [PubMed: 20183947] 
34. Eversley R, Estrin D, Dibble S, Wardlaw L, Pedrosa M, Favila-Penney W. Post-treatment 
symptoms among ethnic minority breast cancer survivors. Oncol Nurs Forum. 2005; 32:250–256. 
[PubMed: 15759063] 
35. Ahluwalia IB, Mack KA, Murphy W, Mokdad AH, Bales VS. State-specific prevalence of selected 
chronic disease-related characteristics--Behavioral Risk Factor Surveillance System, 2001. 
MMWR Surveill Summ. 2003; 52:1–80. [PubMed: 14532868] 
36. Tammemagi CM, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D. Comorbidity and 
survival disparities among black and white patients with breast cancer. Jama. 2005; 294:1765–
1772. [PubMed: 16219879] 
37. Woods LM, Rachet B, Coleman MP. Origins of socio-economic inequalities in cancer survival: a 
review. Ann Oncol. 2006; 17:5–19. Epub 2005 Sep 2. [PubMed: 16143594] 
Keegan et al. Page 10













38. Parsons HM, Harlan LC, Seibel NL, Stevens JL, Keegan TH. Clinical trial participation and time 
to treatment among adolescents and young adults with cancer: does age at diagnosis or insurance 
make a difference? J Clin Oncol. 2011; 29:4045–4053. [PubMed: 21931022] 
39. Jagsi R, Abrahamse P, Hawley ST, Graff JJ, Hamilton AS, Katz SJ. Underascertainment of 
radiotherapy receipt in Surveillance, Epidemiology, and End Results registry data. Cancer. 2012; 
118:333–341. [PubMed: 21717446] 
40. Noone AM, Lund JL, Mariotto A, Cronin K, McNeel T, Deapen D, et al. Comparison of SEER 
Treatment Data With Medicare Claims. Med Care. 2014
41. Giordano SH, Kuo YF, Duan Z, Hortobagyi GN, Freeman J, Goodwin JS. Limits of observational 
data in determining outcomes from cancer therapy. Cancer. 2008; 112:2456–2466. [PubMed: 
18428196] 
42. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International 
Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J. Med. 1998; 339:1506–
1514. [PubMed: 9819449] 
43. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and 
application of a census-based methodology. Am J Public Health. 1992; 82:703–710. [PubMed: 
1566949] 
44. Clegg LX, Reichman ME, Hankey BF, Miller BA, Lin YD, Johnson NJ, et al. Quality of race, 
Hispanic ethnicity, and immigrant status in population-based cancer registry data: implications for 
health disparity studies. Cancer Causes Control. 2007; 18:177–187. [PubMed: 17219013] 
45. Gomez SL, Glaser SL. Misclassification of race/ethnicity in a population-based cancer registry 
(United States). Cancer Causes Control. 2006; 17:771–781. [PubMed: 16783605] 
46. Adams SH, Newacheck PW, Park MJ, Brindis CD, Irwin CE Jr. Health insurance across 
vulnerable ages: patterns and disparities from adolescence to the early 30s. Pediatrics. 2007; 
119:e1033–e1039. [PubMed: 17473076] 
Keegan et al. Page 11














Percentage (%) of adolescent and young adult Hodgkin lymphoma patients undergoing 
radiation therapy by year of diagnosis, California, 1988–2011.
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Kaplan-Meier curve of Hodgkin lymphoma (HL)-specific survival in adolescent and young 
adult patients, by combined-modality therapy and stage of disease (stage I/II, stage III/IV), 
California, 1988–2011. The vertical axis represents survival probability; the horizontal axis 
represents survival time in years. Combined-modality therapy (dotted black line), radiation 
therapy only (solid black line), chemotherapy only (dotted grey line), no or unknown 
therapy (solid grey line).
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